Peptides and combination of peptides for use in immunotherapy against various tumors

Patent metadata

Field	Value
Publication number	US-11407807-B2
Application number	US-202117384330-A
Country	US
Kind code	B2
Filing date	Jul 23, 2021
Priority date	Mar 27, 2015
Publication date	Aug 9, 2022
Grant date	Aug 9, 2022

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

First claim

The invention claimed is:

1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of TLHDQVHLL (SEQ ID NO: 264), wherein the cancer is non-small cell lung cancer, prostate cancer and benign prostate hyperplasia, ovarian cancer, uterine cancer, breast cancer, gallbladder adenocarcinoma and cholangiocarcinoma, or melanoma.

2. The method of claim 1 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.

3. The method of claim 1 , further comprising administering to said patient an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

4. The method of claim 1 , wherein the cancer is non-small cell lung cancer.

5. The method of claim 1 , wherein the cancer is prostate cancer and benign prostate hyperplasia.

6. The method of claim 1 , wherein the cancer is ovarian cancer.

7. The method of claim 1 , wherein the cancer is uterine cancer.

8. The method of claim 1 , wherein the cancer is breast cancer.

9. The method of claim 1 , wherein the cancer is gallbladder adenocarcinoma and cholangiocarcinoma.

10. The method of claim 1 , wherein the cancer is melanoma.

11. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of TLHDQVHLL (SEQ ID NO: 264), wherein the cancer is non-small cell lung cancer, prostate cancer and benign prostate hyperplasia, ovarian cancer, uterine cancer, breast cancer, gallbladder adenocarcinoma and cholangiocarcinoma, or melanoma.

12. The method of claim 11 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.

13. The method of claim 11 , further comprising administering to said patient an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

14. The method of claim 11 , wherein the cancer is non-small cell lung cancer.

15. The method of claim 11 , wherein the cancer is prostate cancer and benign prostate hyperplasia.

16. The method of claim 11 , wherein the cancer is ovarian cancer.

17. The method of claim 11 , wherein the cancer is uterine cancer.

18. The method of claim 11 , wherein the cancer is breast cancer.

19. The method of claim 11 , wherein the cancer is gallbladder adenocarcinoma and cholangiocarcinoma.

20. The method of claim 11 , wherein the cancer is melanoma.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Mahr Andrea
• Weinschenk Toni
• Schoor Oliver
• Fritsche Jens
• Singh Harpreet
• Stevermann Lea

Classifications

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• A61K2239/31

  characterized by the route of administration · CPC title

• A61K2239/46

  characterised by the cancer treated · CPC title

• G01N2800/00

  Detection or diagnosis of diseases · CPC title

• A61K2039/57

  characterised by the type of response, e.g. Th1, Th2 · CPC title